Editas Medicine (EDIT) Intangibles (2020)
Editas Medicine (EDIT) posted quarterly Intangibles of $5.0 million for Q4 2020, little changed quarter-over-quarter from $5.0 million in Q3 2020.
Powered by 
Analysis
Editas Medicine (EDIT) Intangibles (2020) Analysis & Trends
Editas Medicine (EDIT) has reported Intangibles for 1 consecutive years, with $5.0 million the latest figure, recorded in Q4 2020.
- In Q4 2020, Intangibles changed N/A year-over-year to $5.0 million; the TTM figure through Dec 2020 stood at $5.0 million (changed N/A YoY), while the FY2020 annual figure was $5.0 million, changed N/A from the prior year.
- Intangibles was little changed at $5.0 million in Q4 2020 per EDIT's latest filing, from $5.0 million in the prior quarter.
- Across five years, Intangibles topped out at $5.0 million in Q3 2020 and bottomed at $5.0 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 63.28 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 60.96 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |